IDEX Biometrics (IDEX) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
5 Jun, 2025Executive summary
Achieved Mastercard and Visa certification for IDEX Pay platform, enabling global biometric card launches and new market entry in Japan with LIFECARD, launch planned for H1 2025.
Reached scale manufacturing quality with key partners; KONA I became first Mastercard-certified manufacturer for both PVC and metal biometric cards.
Completed rights issue in November, broadening retail investor participation and strengthening capital base.
Streamlined operations, reduced workforce, and closed most activities in China and US subsidiaries.
Financial highlights
No product revenue in Q4 2024; total revenue $24k, down from $484k in Q4 2023 due to lower sensor shipments.
Net loss for Q4 2024 was $2.1 million; adjusted net loss was $4.6 million.
Operating expenses (excluding cost of products sold and bad debt) were $2.4 million, below target.
Non-cash goodwill impairment of $1.0 million recorded in Q4 2024.
Cash balance at December 31, 2024, was $2.0 million, down from $11.4 million a year earlier.
Outlook and guidance
Biometric smart card market expected to reach 37 million cards by 2028; IDEX aims to capture significant share.
LIFE CARD commercial deployment in Japan targeted for H1 2025; India market pending regulatory approval.
Three access products in commercial ramp-up, with launches planned in Q1 and Q3 2025.
Confident in long-term growth driven by biometric card adoption for multifactor authentication.
Market launches delayed in some regions due to political instability, but pipeline remains strong.
Latest events from IDEX Biometrics
- Record backlog, improved margins, and accelerated commercial activity signal a strong 2026 outlook.IDEX
Q1 2026 - Certified biometric products launched, costs cut, but liquidity and sales targets remain challenges.IDEX
Q4 2025 - Q3 2025 saw a 60% OPEX drop, new biometric card launches, and ongoing liquidity risk.IDEX
Q3 2025 - Biometric access cards drive growth, aiming for breakeven in Q4 2025.IDEX
Company Presentation - Cost reductions and new funding support ongoing operations amid continued losses and product launches.IDEX
Q2 2025 - Q3 saw cost cuts, capital raised, and major biometric card approvals amid market risks.IDEX
Q3 2024 - Q2 revenue was $0.4M, margin 40%, costs down, but liquidity and growth risks remain.IDEX
Q2 2024 - Q1 2025 saw a $4.1M net loss, liquidity strain, and urgent need for new funding.IDEX
Q1 2025